# Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

> **NCT00033371** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 205 (actual)

## Conditions studied

- Colorectal Cancer
- Familial Adenomatous Polyposis

## Interventions

- **DRUG:** Celecoxib
- **OTHER:** Placebo
- **DRUG:** eflornithine
- **OTHER:** Laboratory biomarker analysis
- **OTHER:** Questionnaire administration

## Key facts

- **NCT ID:** NCT00033371
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12-13
- **Primary completion:** 2009-02-24
- **Final completion:** 2009-03-24
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2020-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00033371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00033371, "Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00033371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*